Searched for
PHARMACEUTICAL INVESTMENTS
Sankaran Naren favours banks, power as oil risks loomSankaran Naren, CIO of ICICI Prudential Asset Management, remains bullish on banks, power utilities, oil refiners and pharmaceuticals, citi...- Piramal Pharma to focus on policy, not Trump tariff tweets: Nandini PiramalPiramal Pharma will focus on policy actions amid tariff concerns. Its global manufacturing network offers a significant advantage. The comp...
- ChrysCapital acquires controlling 70.68% stake in Novartis India listed unit in first majority pharma investmentChrysCapital has acquired a controlling interest in Novartis India Limited, representing its inaugural investment in India's pharmaceutical...
- India takes action against 90% of inspected high-risk pharmaceutical facilities, regulator saysAmid increasing global concerns over Indian pharmaceuticals, India's drug regulator is rigorously addressing high-risk manufacturing sites....
- Motilal Oswal raises mid and smallcap allocation to 50%, stays neutral on Indian equitiesMotilal Oswal Private Wealth favors Indian mid and small-cap stocks. They are increasing allocations to these segments by ten percentage po...
- BDR Pharmaceuticals eyes controlling stake in Acme FormulationPAG acquired a controlling stake in Acme Formulation for $145 million (?1,054 crore) through its PAG Asia III buyout fund in 2021. Founder ...
- OpenAI to triple workforce at Dublin European headquarters to 350The AI pioneer said it currently employs over 100 people at its Dublin office, which opened in 2023, and that it plans to hire 250 more ov...
- Tariff on generic drugs: Loud announcement, little consequence? 7 pharma stocks with upside potential of up to 31%The threat of a US tariff on Indian pharma is no longer a vague fear; or at least that is what President Trump wants us to believe. There i...
- Pharma mutual funds top return charts across horizons. Should investors chase the rally or stay cautious?Pharma mutual funds are leading returns in CY2026, driven by strong earnings, defensive demand, and US export growth. Despite recent outper...
- US tariff proposal wake-up call for Indian pharma to diversify, innovate: ExpertsUS pharma tariffs: Experts have urged a shift towards global diversification and prioritising innovation for Indian pharma to lessen market...
- Parliament watch: FTA exports rise, PLI payouts growIndia's merchandise exports to its free trade agreement (FTA) partner countries rose 25% year-on-year to $43.14 billion in the April-June q...
- Govt disburses Rs 35,354 crore as on March 31 under PLI schemes: Jitin PrasadaProduction Linked Incentive schemes, which aim to boost manufacturing and attract significant investments, have disbursed Rs 35,354 crore t...
- Pharma deal activity hits four-quarter low, but mega Sun Pharma acquisition drives valueIndia's pharma and healthcare sector recorded 65 deals worth $13.9 billion in Q2 CY2026, with volumes falling 17% quarter-on-quarter to a f...
- Tariffs alone will not produce sustainable generic medicine in US: IPAThe Indian Pharmaceutical Alliance believes tariffs alone will not build US generic drug manufacturing. Broader reforms are needed for fair...
- Food products lead PLI job creation, outpace electronics and pharmaFood processing leads PLI employment, creating jobs with minimal investment. Electronics manufacturing attracted significant capital but ge...
- Indian pharma firms may yet survive Trump's 200% tariff bombshellDonald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say...
- 200% Trump tariff shock? India’s cheap pills may still beat US rivalsUS President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical expor...
- Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% stormTrump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufactur...
- Trump announces new generic drugs tariff plan: No tariffs for 2 years, then 100%, and then 200%For Indian exporters, the two-year tariff-free period offers additional time to reassess supply chains and investment plans. While the imme...
- Sun Pharma, Cipla & other pharma stocks shed over 2% as Trump announces up to 200% tariffs on generic drugs from 2028Pharma stocks, including Sun Pharma, Cipla, Lupin and Dr Reddy's, fell up to 2.5% after US President Donald Trump announced a phased tariff...
Load More
